nach oben

Erschienen in:

22.03.2018 | Review Article

Cytokine Responses in Severe Traumatic Brain Injury: Where There Is Smoke, Is There Fire?

verfasst von: Colin Casault, Abdulaziz S. Al Sultan, Mohammad Banoei, Philippe Couillard, Andreas Kramer, Brent W. Winston

Erschienen in: Neurocritical Care | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

This scoping review will discuss the basic functions and prognostic significance of the commonly researched cytokines implicated in severe traumatic brain injury (sTBI), including tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), transforming growth factor-β (TGF-β), substance P, and soluble CD40 ligand (sCD40L). A scoping review was undertaken with an electronic search for articles from the Ovid MEDLINE, PUBMED and EMBASE databases from 1995 to 2017. Inclusion criteria were original research articles, and reviews including both animal models and human clinical studies of acute (< 3 months) sTBI. Selected articles included both isolated sTBI and sTBI with systemic injury. After applying the inclusion criteria and removing duplicates, 141 full-text articles, 126 original research articles and 15 review articles, were evaluated in compiling this review paper. A single reviewer, CC, completed the review in two phases. During the first phase, titles and abstracts of selected articles were reviewed for inclusion. A second evaluation was then conducted on the full text of all selected articles to ensure relevancy. From our current understanding of the literature, it is unlikely a single biomarker will be sufficient in accurately prognosticating patients with sTBI. Intuitively, a more severe injury will demonstrate higher levels of inflammatory cytokines which may correlate as a marker of severe injury. This does not mean, necessarily, these cytokines have a direct and causal role in the poor outcome of the patient. Further research is required to better delineate the complex systemic inflammatory and CNS interactions that occur during sTBI before they can be applied as a reliable prognostic tool.

Corrigan JD, Selassie AW, Orman JA. The epidemiology of traumatic brain injury. J Head Trauma Rehabil. 2010;25(2):72–80.CrossRefPubMed

Plesnila N. The immune system in traumatic brain injury. Curr Opin Pharmacol. 2016;26:110–7.CrossRefPubMed

Lenzlinger PM, Morganti-Kossmann MC, Laurer HL, McIntosh TK. The duality of the inflammatory response to traumatic brain injury. Mol Neurobiol. 2001;24(1–3):169–81.PubMed

Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–89.CrossRefPubMed

Crespo AR, Da Rocha AB, Jotz GP, et al. Increased serum sFas and TNFalpha following isolated severe head injury in males. Brain Inj. 2007;21(4):441–7.CrossRefPubMed

Morganti-Kossmann MC, Hans VH, Lenzlinger PM, et al. TGF-beta is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood–brain barrier function. J Neurotrauma. 1999;16(7):617–28.CrossRefPubMed

Roberts DJ, Jenne CN, Leger C, et al. Association between the cerebral inflammatory and matrix metalloproteinase responses after severe traumatic brain injury in humans. J Neurotrauma. 2013;30(20):1727–36.CrossRefPubMed

Winter CD, Pringle AK, Clough GF, Church MK. Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. Brain. 2004;127(Pt 2):315–20.CrossRefPubMed

Kamm K, Vanderkolk W, Lawrence C, Jonker M, Davis AT. The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J Trauma. 2006;60(1):152–7.CrossRefPubMed

10.

Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav Immun. 2012;26(8):1191–201.CrossRefPubMed

11.

Nwachuku EL, Puccio AM, Adeboye A, et al. Time course of cerebrospinal fluid inflammatory biomarkers and relationship to 6-month neurologic outcome in adult severe traumatic brain injury. Clin Neurol Neurosurg. 2016;149:1–5.CrossRefPubMed

12.

Constantine G, Buliga M, Mi Q, et al. Dynamic profiling: modeling the dynamics of inflammation and predicting outcomes in traumatic brain injury patients. Front Pharmacol. 2016;7:383.CrossRefPubMedPubMedCentral

13.

Maier B, Lefering R, Lehnert M, et al. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28:668–74.PubMed

14.

Stein DM, Lindel AL, Murdock KR, et al. Use of serum biomarkers to predict secondary insults following severe traumatic brain injury. Shock. 2012;37(6):563–8.CrossRefPubMed

15.

Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci. 2001;2(10):734–44.CrossRefPubMed

16.

Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO. Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study. J Neurotrauma. 2009;26(8):1251–62.CrossRefPubMed

17.

Wright DW, Yeatts SD, Silbergleit R, et al. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med. 2014;371(26):2457–66.CrossRefPubMedPubMedCentral

18.

Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296(5573):1634–5.CrossRefPubMed

19.

D’Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci. 2009;29(7):2089–102.CrossRefPubMedPubMedCentral

20.

Qiu J, Whalen MJ, Lowenstein P, et al. Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans. J Neurosci. 2002;22(9):3504–11.CrossRefPubMed

21.

Sullivan PG, Bruce-Keller AJ, Rabchevsky AG, et al. Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J Neurosci. 1999;19(15):6248–56.CrossRefPubMed

22.

Maier B, Lehnert M, Laurer HL, et al. Delayed elevation of soluble tumor necrosis factor receptors p75 and p55 in cerebrospinal fluid and plasma after traumatic brain injury. Shock. 2006;26(2):122–7.CrossRefPubMed

23.

Di Battista AP, Rhind SG, Hutchison MG, et al. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflamm. 2016;13:40.CrossRef

24.

Bermpohl D, You Z, Lo EH, Kim HH, Whalen MJ. TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice. J Cereb Blood Flow Metab. 2007;27(11):1806–18.CrossRefPubMed

25.

Scherbel U, Raghupathi R, Nakamura M, et al. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci USA. 1999;96(15):8721–6.CrossRefPubMed

26.

Longhi L, Perego C, Ortolano F, et al. Tumor necrosis factor in traumatic brain injury: effects of genetic deletion of p55 or p75 receptor. J Cereb Blood Flow Metab. 2013;33(8):1182–9.CrossRefPubMedPubMedCentral

27.

Lim SW, Shiue YL, Liao JC, et al. Simvastatin therapy in the acute stage of traumatic brain injury attenuates brain trauma-induced depression-like behavior in rats by reducing neuroinflammation in the hippocampus. Neurocrit Care. 2016;26:122–32.CrossRef

28.

Toulmond S, Rothwell NJ. Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res. 1995;671(2):261–6.CrossRefPubMed

29.

Hadjigeorgiou GM, Paterakis K, Dardiotis E, et al. IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury. Neurology. 2005;65(7):1077–82.CrossRefPubMed

30.

Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med. 2000;191(2):303–12.CrossRefPubMedPubMedCentral

31.

Diamond ML, Ritter AC, Failla MD, et al. IL-1beta associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia. 2015;56(7):991–1001.CrossRefPubMed

32.

Li B, Mahmood A, Lu D, et al. Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery. 2009;65(1):179–85 (discussion 85–6).CrossRefPubMedPubMedCentral

33.

Schneider EB, Efron DT, MacKenzie EJ, et al. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. J Trauma. 2011;71(4):815–9.CrossRefPubMed

34.

Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev. 1998;9(3–4):259–75.CrossRefPubMed

35.

Di Santo E, Alonzi T, Fattori E, et al. Overexpression of interleukin-6 in the central nervous system of transgenic mice increases central but not systemic proinflammatory cytokine production. Brain Res. 1996;740:239–44.CrossRefPubMed

36.

Raheja A, Sinha S, Samson N, et al. Serum biomarkers as predictors of long-term outcome in severe traumatic brain injury: analysis from a randomized placebo-controlled phase II clinical trial. J Neurosurg. 2016;125(3):631–41.CrossRefPubMed

37.

Chiaretti A, Antonelli A, Mastrangelo A, et al. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma. 2008;25(3):225–34.CrossRefPubMed

38.

Dalla Libera AL, Regner A, de Paoli J, et al. IL-6 polymorphism associated with fatal outcome in patients with severe traumatic brain injury. Brain Inj. 2011;25(4):365–9.CrossRefPubMed

39.

Woiciechowsky C, Schoning B, Cobanov J, et al. Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. J Trauma. 2002;52(2):339–45.PubMed

40.

Aisiku IP, Yamal JM, Doshi P, et al. Plasma cytokines IL-6, IL-8, and IL-10 are associated with the development of acute respiratory distress syndrome in patients with severe traumatic brain injury. Crit Care. 2016;20:288.CrossRefPubMedPubMedCentral

41.

Wagner N, Akbarpour A, Mors K, et al. Alcohol intoxication reduces systemic interleukin-6 levels and leukocyte counts after severe TBI compared with not-intoxicated TBI patients. Shock. 2016;46:261–9.CrossRefPubMed

42.

Hergenroeder GW, Moore AN, McCoy JP Jr, et al. Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury. J Neuroinflamm. 2010;7:19.CrossRef

43.

Lorente L, Martin MM, Lopez P, et al. Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury. PLoS ONE. 2014;9(4):e94370.CrossRefPubMedPubMedCentral

44.

Jia F, Yin YH, Gao GY, et al. MMP-9 inhibitor SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat. J Neurotrauma. 2014;31(13):1225–34.CrossRefPubMedPubMedCentral

45.

Tejima E, Guo S, Murata Y, et al. Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma. 2009;26(11):1935–41.CrossRefPubMedPubMedCentral

46.

Martinou J, Le Van Thai A, Valette A, Weber M. Transforming growth factor β1 is a potent survival factor for rat embryo motoneurons in culture. Dev Brain Res. 1990;52:175–81.CrossRef

47.

Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1(3):169–78.CrossRefPubMed

48.

Beck K, Schachtrup C. Vascular damage in the central nervous system: a multifaceted role for vascular-derived TGF-beta. Cell Tissue Res. 2012;347(1):187–201.CrossRefPubMed

49.

Sillesen M, Johansson PI, Rasmussen LS, et al. Platelet activation and dysfunction in a large-animal model of traumatic brain injury and hemorrhage. J Trauma Acute Care Surg. 2013;74(5):1252–9.CrossRefPubMed

50.

Wang XY, Ba YC, Xiong LL, et al. Endogenous TGFbeta1 plays a crucial role in functional recovery after traumatic brain injury associated with Smad3 signal in rats. Neurochem Res. 2015;40(8):1671–80.CrossRefPubMed

51.

Moon L, Fawcett J. Reduction in CNS scar formation without concomitant increase in axon regeneration following treatment of adult rat brain with a combination of antibodies to TGFb1and b2. Eur J Neurosci. 2001;14(10):1667–77.CrossRefPubMed

52.

Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM. Transforming growth factor-beta1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-kappaB pathways. J Neuroinflamm. 2010;7:88.CrossRef

53.

Wyss-Coray T, Borrow P, Brooker MJ, Mucke L. Astroglial overproduction of TGF-beta 1 enhances inflammatory central nervous system disease in transgenic mice. J Neuroimmunol. 1997;77(1):45–50.CrossRef

54.

Brionne T, Tesseur I, Masliah E, Wyss-Coray T. Loss of TGFbeta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron. 2003;40(6):1133–45.CrossRefPubMed

55.

Kohta M, Kohmura E, Yamashita T. Inhibition of TGF-beta1 promotes functional recovery after spinal cord injury. Neurosci Res. 2009;65(4):393–401.CrossRefPubMed

56.

Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain. 2007;130(Pt 2):535–47.CrossRefPubMed

57.

Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J Neurosci. 2009;29(28):8927–35.CrossRefPubMedPubMedCentral

58.

Mashaghi A, Marmalidou A, Tehrani M, et al. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016;73:4249–64.CrossRefPubMedPubMedCentral

59.

Ghabriel M, Lu M, Leigh C, Cheung W, Allt G. Substance P-induced enhanced permeability of dura mater microvessels is accompanied by pronounced ultrastructural changes, but is not dependent on the density of endothelial cell anionic sites. Acta Neuropathol. 1999;97:297–305.CrossRefPubMed

60.

Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab. 2009;29(8):1388–98.CrossRefPubMed

61.

Donkin JJ, Cernak I, Blumbergs PC, Vink R. A substance P antagonist reduces axonal injury and improves neurologic outcome when administered up to 12 hours after traumatic brain injury. J Neurotrauma. 2011;28(2):217–24.CrossRefPubMed

62.

Wang Q, Oyarzabal E, Wilson B, Qian L, Hong JS. Substance P enhances microglial density in the substantia nigra through neurokinin-1 receptor/NADPH oxidase-mediated chemotaxis in mice. Clin Sci (Lond). 2015;129(8):757–67.CrossRef

63.

Vishwanath R, Mukherjee R. Substance P promotes lymphocyte-endothelial cell adhesion preferentially via LFA-1/ICAM-l interactions. J Neuroimmunol. 1996;71(1–2):163–71.CrossRefPubMed

64.

Martin FC, Charles AC, Sanderson MJ, Merrill JE. Substance P stimulates IL-1 production by astrocytes via intracellular calcium. Brain Res. 1992;599(1):13–8.CrossRefPubMed

65.

Zhu J, Qu C, Lu X, Zhang S. Activation of microglia by histamine and substance P. Cell Physiol Biochem. 2014;34(3):768–80.CrossRefPubMed

66.

Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-B. J Immunol. 2000;165(10):5606–11.CrossRefPubMed

67.

Lorente L, Martin MM, Almeida T, et al. Serum substance P levels are associated with severity and mortality in patients with severe traumatic brain injury. Crit Care. 2015;19:192.CrossRefPubMedPubMedCentral

68.

Furman MI, Krueger LA, Linden MD, et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004;43(12):2319–25.CrossRefPubMed

69.

Geraldes P, Gagnon S, Hadjadj S, et al. Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ERalpha-mediated pathway. Cardiovasc Res. 2006;71(3):566–73.CrossRefPubMed

70.

Wagner AH. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood. 2002;99(2):520–5.CrossRefPubMed

71.

Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 1995;92(10):4342–6.CrossRefPubMed

72.

Mach F, Sukhova G, Bourcier T, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40–CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997;4(94):1931–6.CrossRef

73.

Prasad KS, Andre P, He M, et al. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA. 2003;100(21):12367–71.CrossRefPubMed

74.

Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8(3):247–52.CrossRefPubMed

75.

Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100(6):614–20.CrossRefPubMed

76.

Garlichs CD, Kozina S, Fateh-Moghadam S, et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke. 2003;34(6):1412–8.CrossRefPubMed

77.

Lorente L, Martin MM, Varo N, et al. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Crit Care. 2011;15(2):R97.CrossRefPubMedPubMedCentral

78.

Lorente L, Martin MM, Gonzalez-Rivero AF, et al. Serum soluble CD40 Ligand levels are associated with severity and mortality of brain trauma injury patients. Thromb Res. 2014;134(4):832–6.CrossRefPubMed

79.

Chen XD, Sun J, Lu C, et al. The prognostic value of plasma soluble CD40 ligand levels following aneurysmal subarachnoid hemorrhage. Thromb Res. 2015;136(1):24–9.CrossRefPubMed

80.

Kinlay S, Schwartz GG, Olsson AG, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110(4):386–91.CrossRefPubMed

81.

Kumar RG, Rubin JE, Berger RP, Kochanek PM, Wagner AK. Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury. Brain Behav Immun. 2016;53:183–93.CrossRefPubMed

82.

Helmy A, Guilfoyle MR, Carpenter KL, et al. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J Cereb Blood Flow Metab. 2014;34(5):845–51.CrossRefPubMedPubMedCentral

83.

Morganti-Kossmann MC, Hans VHJ, Lenzlinger PM, et al. TGF-β is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood–brain barrier function. J Neurotrauma. 1999;16(7):617–28.CrossRefPubMed

Titel: Cytokine Responses in Severe Traumatic Brain Injury: Where There Is Smoke, Is There Fire?
verfasst von: Colin Casault
Abdulaziz S. Al Sultan
Mohammad Banoei
Philippe Couillard
Andreas Kramer
Brent W. Winston
Publikationsdatum: 22.03.2018
Verlag: Springer US
Erschienen in: Neurocritical Care / Ausgabe 1/2019
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI: https://doi.org/10.1007/s12028-018-0522-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Withdrawal of Life-Sustaining Treatments in Perceived Devastating Brain Injury: The Key Role of Uncertainty

Safety, Feasibility, and Efficiency of a New Cooling Device Using Intravenous Cold Infusions for Fever Control

Continuous Assessment of “Optimal” Cerebral Perfusion Pressure in Traumatic Brain Injury: A Cohort Study of Feasibility, Reliability, and Relation to Outcome

Attitudes of Nurses Toward Disability and Treatment in Space-Occupying Middle Cerebral Artery Stroke